^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FOXO3 rs4946935

i
Other names: FOXO3, AF6q21, FKHRL1, FOXO2, FOXO3A, Forkhead box O3
Entrez ID:
Related biomarkers:
Associations
Trials
2years
FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. (PubMed, Acta Pharm Sin B)
This study reveals that FOXO3 mutation, leading to autophagic imbalance, plays important role in gefitinib-induced hepatotoxicity, especially for patients with high concentration of gefitinib. In conclusion, FOXO3 mutation is an effective predictor and erlotinib might be an appropriately and well-tolerated treatment option for patients carrying rs4946935 AA.
Journal
|
FOXO3 (Forkhead box O3)
|
FOXO3 rs4946935
|
erlotinib • gefitinib
over4years
[VIRTUAL] FOXO3 polymorphisms were correlated with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer. (ASCO 2020)
FOXO3 rs4946935 and FOXO3 rs75544369 are predictive biomarkers for gefitinib-induced hepatotoxicity in NSCLC patients. The mechanism underlying the association between FOXO3 polymorphisms and gefitinib-induced hepatotoxicity are worth investigating in further studies. Research Funding: National Natural Science Foundation of China
Clinical
|
EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FOXO3 (Forkhead box O3)
|
EGFR mutation • FOXO3 rs4946935 • FOXO3 rs75544369
|
gefitinib